Skip to main content

Table 1 Participants' characteristics (ATP immunogenicity cohort)

From: Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial

  PHiD-CV group
(N = 217)
Control group
(N = 112)
Total
(N = 329)
Gender (%), female/male 50.2/49.8 50.9/49.1 50.5/49.5
Dose 1:    
   mean age ± SD (weeks) 7.1 ± 1.14 7.0 ± 1.16 7.1 ± 1.14
   mean weight ± SD (kg) 4.85 ± 0.76 4.74 ± 0.81 4.81 ± 0.78
   mean weight-for-age Z-score ± SD -0.45 ± 1.10 -0.61 ± 1.17 -0.50 ± 1.13
Dose 2:    
   mean age ± SD (weeks) 12.2 ± 1.28 12.1 ± 1.33 12.1 ± 1.30
   mean weight ± SD (kg) 5.80 ± 0.87 5.72 ± 0.93 5.78 ± 0.89
   mean weight-for-age Z-score ± SD -0.39 ± 1.14 -0.49 ± 1.22 -0.43 ± 1.17
Dose 3:    
   mean age ± SD (weeks) 17.1 ± 1.25 17.0 ± 1.32 17.1 ± 1.27
   mean weight ± SD (kg) 6.53 ± 0.90 6.39 ± 0.95 6.48 ± 0.92
   mean weight-for-age Z-score ± SD -0.31 ± 1.08 -0.50 ± 1.17 -0.37 ± 1.11
Mean interval between dose 3 and blood sampling visit (days) 33.4 33.3 33.4
  1. NOTE. SD, standard deviation; N, number of subjects